BRANFORD, Conn., July 9, 2018 /PRNewswire/ — Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic stroke, announced today the initiation of a Phase 1 clinical trial in healthy volunteers of its first-in-class drug candidate, AER-271.

Link to Press Release